Vascular doses of drugs will be used, including in group ASA and Rivaroxaban: 1 x/day ASA 75-100 mg + 2 x/day 2.5 mg Rivaroxaban (Xarelto).

Vascular doses of drugs will be used, including in group ASA: 1 x/day ASA 75-100 mg

Blood -EDTA samples, Serum samples, DNA samples

Peripheral Arterial Disease

Rivaroxaban

Influence of Rivaroxaban for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic PAD

Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial

Number of participants diagnozed with ischemic or hemorrhagic stroke

Number of participants diagnozed with Myocardial infarction

Number of participants who died because of Cardiovascular causes

Death for any reason not related to accidents.

Number of participants diagnozed with Acute limb ischaemia definied as limb threatening ischaemia with evidence of acute arterial obstruction by radiological criteria or a new pulse deficit leading to an intervention (ie, surgery, thrombolysis, peripheral angioplasty, or amputation.

Number of participants diagnozed with Major limb amputation was defined as amputations due to a vascular event above the forefoot, or defined as minor amputation if involving the forefoot and digits.

Change in the distance of intermittent claudication in the test according to Gardner's protocol

Change in the maximal distance of intermittent claudication in the test according to Gardner's protocol

Bleeding that directly results in death within 7 d.

Non-fatal symptomatic intracranial haemorrhage.

Non-fatal, non-intracranial haemorrhage symptomatic bleeding into a critical organ

Other major bleeding (surgical site bleeding requiring). reoperation or bleeding leading to hospitalization)

Fatal or symptomatic bleeding into a critical organ

Major bleeding according to modified the International Society on Thrombosis and Haemostasis (ISTH) criteria for major bleeding, defined as the composite of bleeding that was fatal, symptomatic bleeding into a critical organ, surgical site requiring reoperation, or requiring hospitalization (including presentation to an acute care facility without an overnight stay).(ISTH)/Scientific and Standardization Committee (SSC) definitions

Minor bleeding: A clinically relevant minor bleed: an acute or subacute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following:
A hospital admission for bleeding, or
A physician guided medical or surgical treatment for bleeding, or
A change in antithrombotic therapy (including interruption or discontinuation of study drug).

Sites of bleeding - other than: gastrointestinal, intracranial, genitourinary, ocular, skin, respiratory.

These data will be made available on reasonable request

Poznan University of Medical Sciences

Poznan University of Physical Education

Institute of Human Genetics, Polish Academy of Sciences

Cerebral Infarction

MCI-9042

Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study

Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Clinical-pharmacological Dose-response Study.

General Manager, Clinical Research Department I

Mitsubishi Tanabe Pharma Corporation

Aspirin

Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)

Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A Randomized, Double-Blind, Aspirin-Controlled Trial

5 hydroxytryptamine/infart

Influence of Rivaroxaban for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic PAD

Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study

Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)

La base de dades d’herbes medicinals més completa avalada per la ciència